

September 19, 2022

Corporate Relationship Department M/s. BSE Ltd. Dalal Sreet, Fort <u>Mumbai 400 001</u> Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

Ch. Venkat Ramesh Company Secretary & Compliance Officer



Natco Pharma Limited Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

<u>Ref:PR/08/2022</u>

Press Release

## NATCO gets CTPR launch approval from Delhi High Court

*Hyderabad, India, September 19th, 2022* 

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) today received Order from Hon'ble High Court of Delhi stating that NATCO is allowed to launch *Chlorantraniliprole (CTPR)* and its formulations, through its non-infringing process.

NATCO is the 1<sup>st</sup> Company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) recorded in its Minutes of the 425<sup>th</sup> Meeting held on January 25<sup>th</sup>, 2021, for indigenous manufacture of *Chlorantraniliprole (CTPR) Technical 93.00% w/w min.* under Section 9(3). CTPR technical is formulated into broad-spectrum insecticides used across wide range of crops for pest management.

NATCO estimates the current market size of CTPR containing products in India to be over INR 2000 crores. The Company plans to launch its products very shortly.

For NATCO Pharma Limited

CH. Venkat Ramesh Company Secretary & Compliance Officer